[go: up one dir, main page]

BRPI1009392A2 - "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." - Google Patents

"formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."

Info

Publication number
BRPI1009392A2
BRPI1009392A2 BRPI1009392A BRPI1009392A BRPI1009392A2 BR PI1009392 A2 BRPI1009392 A2 BR PI1009392A2 BR PI1009392 A BRPI1009392 A BR PI1009392A BR PI1009392 A BRPI1009392 A BR PI1009392A BR PI1009392 A2 BRPI1009392 A2 BR PI1009392A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
effective amount
pharmaceutically effective
formulation
pharmaceutical
Prior art date
Application number
BRPI1009392A
Other languages
English (en)
Inventor
Claus Christiansen
Morten Asser Karsdal
Original Assignee
Nordic Bioscience As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42199688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1009392(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0904271A external-priority patent/GB0904271D0/en
Priority claimed from GB0910904A external-priority patent/GB0910904D0/en
Priority claimed from GB0912906A external-priority patent/GB0912906D0/en
Application filed by Nordic Bioscience As filed Critical Nordic Bioscience As
Publication of BRPI1009392A2 publication Critical patent/BRPI1009392A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI1009392A 2009-03-12 2010-03-10 "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." BRPI1009392A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0904271A GB0904271D0 (en) 2009-03-12 2009-03-12 Treatment of diabetes and metabolic syndrome
GB0910904A GB0910904D0 (en) 2009-06-24 2009-06-24 Treatment of diabetes and metabolic syndrome
GB0912906A GB0912906D0 (en) 2009-07-24 2009-07-24 Treatment of diabetes and metabolic syndrome
PCT/EP2010/053044 WO2010103045A1 (en) 2009-03-12 2010-03-10 Treatment of diabetes and metabolic syndrome

Publications (1)

Publication Number Publication Date
BRPI1009392A2 true BRPI1009392A2 (pt) 2016-03-08

Family

ID=42199688

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1009392A BRPI1009392A2 (pt) 2009-03-12 2010-03-10 "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."

Country Status (13)

Country Link
US (1) US20120046224A1 (pt)
EP (2) EP2405934B1 (pt)
JP (1) JP5993147B2 (pt)
KR (1) KR101673042B1 (pt)
CN (1) CN102369018B (pt)
AU (1) AU2010223329B2 (pt)
BR (1) BRPI1009392A2 (pt)
CA (1) CA2755068C (pt)
CL (1) CL2011002229A1 (pt)
MX (1) MX2011009559A (pt)
NZ (1) NZ595021A (pt)
RU (1) RU2537181C2 (pt)
WO (1) WO2010103045A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5932279B2 (ja) * 2011-10-07 2016-06-08 ポーラ化成工業株式会社 スクリーニング方法
DK3095484T3 (en) * 2011-11-02 2018-06-25 Keybioscience Ag CALCITONIN MIMETICS FOR THE TREATMENT OF DISEASES AND DISORDERS
US9533022B2 (en) 2011-11-02 2017-01-03 KeyBioscience A/S Peptide analogs for treating diseases and disorders
MX351092B (es) * 2011-11-02 2017-10-02 Keybioscience Ag Analogos peptidicos para tratar enfermedades y trastornos.
CN102380089A (zh) * 2011-11-14 2012-03-21 北京大学 中介素1-53在制备糖代谢紊乱治疗药物中的新用途
US9381199B2 (en) 2012-07-09 2016-07-05 Hetero Research Foundation Linagliptin solid dispersion
WO2014009970A2 (en) * 2012-07-09 2014-01-16 Hetero Research Foundation Linagliptin solid dispersion
BR112015030518A2 (pt) * 2013-06-05 2017-08-29 Salk Inst For Biological Studi Composição farmacêutica, uso de um ou mais agonistas do receptor da vitamina d (vdr), e, método para a redução da atividade biológica do ligante 12 do motivo c-x-c (cxcl12)
TW201625671A (zh) * 2014-09-04 2016-07-16 諾佛 儂迪克股份有限公司 新穎澱粉素及降鈣素受體促效劑
CN105561330B (zh) * 2016-01-25 2018-05-25 四川大学 一种人降钙素-葫芦脲复合制剂及其制备方法
BR112018073688A2 (pt) * 2016-05-20 2019-02-26 Center Laboratories, Inc. método de tratamento de hiperglicemia
RU2699800C2 (ru) * 2017-11-01 2019-09-11 Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ уменьшения гипертензивного эффекта хлорида кобальта кальцитонином
GB201813678D0 (en) * 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
BR112021006823A2 (pt) 2018-10-11 2021-07-27 Intarcia Therapeutics, Inc. polipeptídeos análogos de amilina humana e métodos de uso
US20250099561A1 (en) * 2022-01-21 2025-03-27 Luis Hector BARBEITO ERBA Active immunization for reducing osteoarthritic, neuropathic, and cancer pain

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5359688A (en) 1976-11-11 1978-05-29 Tanpakushitsu Kenkiyuu Shiyour Production of novel polypeptide
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
DE68924372T2 (de) 1988-01-11 1996-05-09 Amylin Pharmaceuticals Inc Behandlung von diabetes mellitus typ 2.
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
US5635478A (en) * 1989-09-18 1997-06-03 Yale University Use of calcitonin gene-related peptide to regulate immune response
JPH0459795A (ja) * 1990-06-26 1992-02-26 Sanwa Kagaku Kenkyusho Co Ltd カルシトニン様活性を有するポリペプチド誘導体及びその用途
US5102666A (en) 1990-09-11 1992-04-07 Oramed, Inc. Calcium polycarbophil controlled release composition and method
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
DK0567626T3 (da) 1991-11-19 2001-12-17 Amylin Pharmaceuticals Inc Amylin-agonist-peptider og anvendelse deraf
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
CZ69596A3 (en) 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
JPH083196A (ja) 1994-06-21 1996-01-09 Sanwa Kagaku Kenkyusho Co Ltd カルシトニン誘導体及びその用途
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5698521A (en) 1995-04-04 1997-12-16 Zymogenetics, Inc. Native calcitonin mimetics
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU6179998A (en) 1997-02-24 1998-09-09 Zymogenetics Inc. Calcitonin mimetics
US6221913B1 (en) 1998-01-21 2001-04-24 Zymogenetics, Inc. Dialkyl ureas as calcitonin mimetics
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
JP2002531518A (ja) 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6780846B1 (en) 1999-09-27 2004-08-24 Elan Corporation, Plc Membrane translocating peptide drug delivery system
JP2001294574A (ja) 2000-04-11 2001-10-23 Suntory Ltd カルシトニン受容体作動物質
GB2368792A (en) 2000-10-06 2002-05-15 Roger Randal Charles New Absorption enhancers
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
GB0109438D0 (en) * 2001-04-17 2001-06-06 Isis Innovation Peptides
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
WO2004084870A1 (en) 2003-03-28 2004-10-07 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
GB0308732D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Absorption enhancers
ES2436152T3 (es) * 2003-07-23 2013-12-27 Novartis Ag Uso de calcitonina en osteoartritis
US20070088163A1 (en) * 2003-09-12 2007-04-19 Kemia, Inc. Modulators of calcitonin and amylin activity
US20070172517A1 (en) 2003-09-17 2007-07-26 Ben-Sasson Shmuel A Compositions capable of facilitation penetration across a biological barrier
NZ549332A (en) * 2004-02-11 2008-11-28 Amylin Pharmaceuticals Inc Amylin family peptides and methods for making and using them
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US20080200563A1 (en) 2004-07-22 2008-08-21 Thiomatrix Forschungs- Und Beratungs- Gmbh Use of Compounds Containing Thiol Groups as Efflux Pump Inhibitors
US7396936B1 (en) 2004-11-09 2008-07-08 Kemia, Inc. Modulators of calcitonin and amylin receptor activity
AU2006256132B2 (en) * 2005-06-09 2010-02-18 Asahi Kasei Pharma Corporation Therapeutic agent and/or prophylactic agent for neurogenic pain
AU2006288703B2 (en) 2005-09-06 2011-09-22 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
ATE515260T1 (de) 2006-03-13 2011-07-15 Advanced In Vitro Cell Technologies S L Stabile nanokapselsysteme für die verabreichung von wirkstoffen
MX2008012678A (es) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
WO2007134151A2 (en) * 2006-05-10 2007-11-22 Smithkline Beecham Corporation Composition and method for increasing cell permeability of a compound
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs

Also Published As

Publication number Publication date
RU2537181C2 (ru) 2014-12-27
WO2010103045A1 (en) 2010-09-16
CA2755068A1 (en) 2010-09-16
JP5993147B2 (ja) 2016-09-14
CA2755068C (en) 2018-11-06
CN102369018B (zh) 2016-08-03
AU2010223329B2 (en) 2016-07-21
KR20120058445A (ko) 2012-06-07
US20120046224A1 (en) 2012-02-23
JP2012520262A (ja) 2012-09-06
EP2762150A1 (en) 2014-08-06
EP2405934B1 (en) 2014-03-26
KR101673042B1 (ko) 2016-11-04
AU2010223329A1 (en) 2011-09-22
RU2011141291A (ru) 2013-04-20
MX2011009559A (es) 2012-01-12
CN102369018A (zh) 2012-03-07
EP2405934A1 (en) 2012-01-18
CL2011002229A1 (es) 2012-04-09
NZ595021A (en) 2013-04-26

Similar Documents

Publication Publication Date Title
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
SMT201400076B (it) Formulazioni farmaceutiche contro l'uso improprio di medicinali
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
HUE053357T2 (hu) Gyógyszerészeti készítmény és annak beadásai
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI0917540A2 (pt) composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI1013988A2 (pt) composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI1009823A2 (pt) "composição compreendendo um sistema de dispensação de droga, conjunto de uma primeira e uma segunda composição, e, kit."

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: KEYBIOSCIENCE AG (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL